Clovis Oncology Undertakes $345 Million Stock Offering

June 27, 2017

Willkie represents biopharmaceutical company Clovis Oncology, Inc. in its underwritten public offering of $345 million of shares of its common stock.

Willkie client Clovis Oncology, Inc. (NASDAQ:CLVS) recently announced an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share. The offering was upsized from $250 million to $300 million. In addition, the underwriters have exercised their full option to purchase an additional 511,363 shares, bringing the total value of the offering to $345 million. The offering closed on June 26.

J. P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers for the offering, and Stifel and SunTrust Robinson Humphrey acted as co-managers.

Based in Boulder, CO, Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.

The transaction was handled by partner Thomas Mark and associates Ted Powers and Neesha Mallavarapu.